



CURRICULUM VITAE

Florencia McAllister, MD

PRESENT TITLE AND AFFILIATION

Primary Appointment

Associate Professor, Department of Clinical Cancer Prevention, The University of Texas
MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of
Texas MD Anderson Cancer Center, Houston, TX

Associate Professor, Department of Immunology, The University of Texas MD Anderson Cancer
Center, Houston, TX

Faculty, Graduate School of Biomedical Sciences, MD Anderson Cancer Center/UT Health,
Houston, TX

CITIZENSHIP

United States
Argentina

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
6767 Bertner Avenue
Houston, TX 77030
Phone: 713-745-0914

EDUCATION

Degree-Granting Education

National University of Rosario Medical School, Rosario, Santa Fe, Argentina, MD, 2000, Medical

Postgraduate Training

Clinical Internship, Carrasco Hospital Infectious Disease Center, Rosario, Santa Fe, Argentina,
Carlos Maturin, MD, 10/2000-6/2001

Postdoctoral Fellowship, Louisiana State University Gene Therapy Program, New Orleans, LA,
Jay K Kolls, MD, 7/2002-8/2003

Postdoctoral Fellowship, Immunology, Children's Hospital of Pittsburgh Immunology and Host
Defense Lab, Pittsburgh, PA, Jay K Kolls, MD, 9/2003-11/2005

Clinical Internship, UPMC Presbyterian University of Pittsburgh Medical Center Internal Medicine
Department, Pittsburgh, PA, Frank J Kroboth, MD, 12/2005-11/2006

Clinical Residency, Internal Medicine, UPMC Presbyterian Shadyside University of Pittsburgh
Medical Center Internal Medicine Department, Pittsburgh, PA, Asher Tulskey, MD, 12/2006-
11/2008

Clinical Research Certificate, Clinical Research Training Program University of Pittsburgh-School
of Medicine, General Internal Medicine Department, Pittsburgh, PA, Wishwa Kapoor, MD, 7/2007-
8/2008

Clinical Fellowship, Clinical Pharmacology Fellowship Johns Hopkins University, Internal
Medicine Department, Baltimore, MD, Craig Hendrix, MD, 1/2009-6/2012

Clinical Fellowship, Medical Oncology Fellowship, Johns Hopkins University, Oncology Department, Baltimore, MD, Ross Donehower, MD, 7/2009-3/2014

Research Fellowship, Tumor Immunology, Johns Hopkins University Oncology Department, Baltimore, MD, Drew Pardoll, MD, PhD, 6/2014-8/2014

CREDENTIALS

Board Certification

Internal Medicine, 7/2010-5/2021

Medical Oncology, 6/2015-5/2025

Licensures

Active

Medical License, TX, Q3735, 4/2015-5/2025

Medical License, FL, TPME2043, 8/2021-8/2099

Medical License, WA, MD61469596, 7/2023-3/2024

Medical License, AZ, 71007, 7/2023-7/2025

Medical License, AL, MD.46935, 7/2023-12/2023

Medical License, LA, 338028, 7/2023-3/2024

Medical License, OK, 42085, 7/2023-7/2024

Medical License, TN, 69244, 7/2023-3/2025

Medical License, GA, 96905, 8/2023-3/2025

Medical License, MS, 32075, 8/2023-6/2024

Inactive

Medical License, MD, D69256, 5/2009-9/2015

EXPERIENCE/SERVICE

Academic Appointments

Postdoctoral Fellow, Gene Therapy Program, New Orleans, LA, 2002-2003

Postdoctoral Research Associate, Department of Immunology, University of Pittsburgh, Pittsburgh, PA, 2003-2005

Medical Resident, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2005-2008

Clinical Research Trainee, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 2007-2008

Fellow, Clinical Pharmacology, Johns Hopkins University, Baltimore, MD, 2009-2012

Fellow, Medical Oncology/ Tumor Immunology, Johns Hopkins Hospital, Baltimore, MD, 2009-2014

Assistant Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2014-8/2020

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2014-8/2020

Faculty, Graduate School of Biomedical Sciences, MD Anderson Cancer Center/UT Health, Houston, TX, 2015-present

Associate Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2020-present

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2020-present

Associate Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2020-present

Administrative Appointments/Responsibilities

Affiliate Member, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-present

Co-Director, GSBS Program in Immunology, Houston, TX, 2000-present

Director, Pancreatic Cancer Genetics/High Risk Clinic, MD Anderson Cancer Center, Houston, TX, 3/2015-present

Other Appointments/Responsibilities

Teaching Assistant, National University of Rosario, Rosario, Santa Fe, Argentina, 3/1995-12/1996

Instructor, National University of Rosario, Rosario, Santa Fe, Argentina, 8/1997-3/1998

Teaching Assistant, National University of Rosario, Rosario, Santa Fe, Argentina, 3/1998-2/2000

Instructor, National University of Rosario, Rosario, Santa Fe, Argentina, 3/2000-6/2002

Lead, Tumor Microbiome, PRIME-TR Microbiome Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2015-present

Graduate Committee Faculty, Texas A&M University, Houston, TX, 2020-present

Member, Diversity Committee- Cancer Biology, Houston, TX, 2020-present

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Infectious Disease Committee, CCP Department Representative, 12/2015-8/2023

CCP Department Faculty Recruitment Committee, Committee Member, 5/2016-present

Immunology Department Faculty Recruitment Committee, Member, 5/2016-present

Focus on Junior Faculty, Committee Member, 8/2016-2018

UT GSBS Admission Committee, Committee Member, 8/2016-2018

GSBS Tumor Immunology Steering Committee, Member, 2019-present

UT Graduate School Tumor Immunology Steering Committee, Member, 6/2019-present

Cancer Biology T32 Diversity Committee- Cancer Biology, Member, 2020-present

Research Policy Advisory Council Monthly, Member, 2022-present

MDA 2022-1 Inquiry Committee, Volunteer, 2023-present

HONORS AND AWARDS

Scholarship NIAID, Tuberculosis and Pulmonary Infections Assembly, 2004

O'Toole Award, University of Pittsburgh, 2009

AACR Basic Science Fellowship, AACR, 2012

ASCO Young Investigator Award, ASCO (CCF), 2012

T32 Training grant in Clinical Pharmacology, NIGMS, 2012

GI ASCO Merit Award, GI ASCO, 2013

AACR/PanCAN Career Development Award, AACR/PanCAN, 2014

New Faculty Award, MD Anderson, 2014

AGA Scholar, AGA, 2016

V Foundation Scholar, V Foundation, 2016

Andrew Sabin Fellow, Sabin Foundation, 2018-2019

Emerson Collective Scholar, 2018

Duncan Family Fellow, 2019

Presidential Recognition for Research Excellence, MD Anderson Cancer Center, 2019

Sharp Innovation Award, SU2C-AACR, 2020-2022

Inaugural Shelby Scholar, 2021-2023

MD Anderson Faculty Scholar Award, The University of Texas MD Anderson Cancer Center, 2021

American Society of Clinical Investigation (Honor Society), 2022

Faculty Scholar Award, MD Anderson Cancer Center, 2022

Mary Beth Maddox Award for Pancreatic Tumor Microbiome Research, Texas Academy of Medicine, Engineering, Science and Technology (TAMEST), 2023

RESEARCH

Grants and Contracts

Funded

Co-Investigator, 5%, Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer, 1U01CA214263-01A1, NIH/NCI, PI - Subrata/Killary, 8/1/2018-7/31/2024, \$6,199,924

Principal Investigator, 20%, Modulating the Gut-Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuppression, RP200173, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2020-2/29/2024, \$2,067,105

Principal Investigator, 20%, Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis (converted into MERIT R37- 7 years support), 1R37CA237384-01A1, NIH/NCI, 9/18/2020-6/30/2025, \$2,025,000 (\$250,000/year)

Principal Investigator, 10%, Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers: TO - Preclinical Testing of CD73 Inhibitors for Pancreatic Cancer Immunoprevention, 75N91019D00021 / 75N91020F00002, NIH/NCI, 9/21/2020-3/15/2024, \$1,191,330

Co-Investigator, 1%, Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer, 1R01CA248731-01A1, NIH/NCI, PI - Kadara, 3/1/2021-2/28/2026, \$3,120,904 (\$441,342/year)

Principal Investigator, 1%, Shelby-Lavine Pancreatic Scholars Program, Shelby-Lavine Pancreatic Scholars Program, 6/1/2021-5/31/2024, \$300,000

Principal Investigator, 10%, Preclinical PREVENT Cancer Program: Evaluation of real-time metabolic imaging biomarkers for detection of pancreatic premalignant lesions, 75N91019D00021/75N91020F00003, NIH/NCI, 9/16/2021-3/15/2024, \$1,166,274

Co-Investigator, 3%, Developing Imaging Biomarkers for Immunotherapy Resistance In Vivo, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Pratip Bhattacharya, 3/1/2022-2/28/2025, \$1,050,000

Co-Investigator, 1%, Developing New Genetically Tractable Chassis for Pancreatic Bacterial Tumor Therapies, Gulf Coast Consortia (GCC), PI - George Lu, 9/1/2022-8/31/2024, \$100,000 (\$50,000/year)

Co-Investigator, 2%, Demystifying Pancreatic Cancer Therapies (DPT), FP00016968, Break Through Cancer, PI - Maitra, 9/21/2022-8/31/2025, \$874,955

Principal Investigator, Learning the Spatial and Functional Identity of Microbes Homing Into Pancreatic Tumors, RCTS-2023-00062100-Y1, MD Anderson Cancer Center, 4/1/2023-3/31/2024, \$75,000

Principal Investigator, 1%, Targeting NETosis to Prevent Liver Metastasis Niche Formation, UTMDACC GI SPORE DRP Program, 6/1/2023-5/31/2024, \$30,000 (\$50,000/year)

Co-Principal Investigator, 5%, A Single-Arm Phase II Study for Evaluating the Safety and Efficacy of Combination of Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) in Patients with Pancreatic Ductal Adenocarcinoma (PDAC), R01CA268046, NIH/NCI, PI - Bailey, 7/1/2023-6/30/2028, \$2,000,000

Co-Principal Investigator, 5%, Real-Time Metabolic Imaging to Interrogate Early Detection and Prevention of Pancreatic Cancer, GRANT13723124, Department of Defense (DOD), PI - Pratip Bhattacharya, PhD, 9/1/2023-8/31/2026, \$518,957 (\$88,534/year)

Co-Principal Investigator, 5%, Preclinical PREVENT Cancer Program: Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer, 75N91019D00021/75N91020F00003, NIH/NCI, PI - McAllister/Bailey/Mills, 9/15/2023-9/14/2026, \$593,572 (\$98,928/year)

Pending

Consultant, 2%, Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer, 2 U01 CA214263-06, NIH/NCI, PI - Subrata Sen, 4/1/2024-3/31/2029, \$4,866,699

Co-Principal Investigator, 10%, Next-generation vaccines for pancreatic cancer interception in high-risk individuals, FP00020016, NIH/NCI, PI - Maitra, 4/1/2024-3/31/2029, \$2,495,737

Internal Advisory Board Member, The University of Texas MD Anderson Cancer Center SPORE in Melanoma, FP00020546, MD Anderson Cancer Center, PI - Michael Davies, 6/1/2024-5/31/2029, \$11,344,001 (\$1,452,984/year)

Co-Investigator, 10%, Improvement of PDAC Vascular Function by Exercise, FP00017833_Res1, NIH/NCI, PI - Schadler, 7/1/2024-6/30/2029, \$3,641,657

Principal Investigator, 20%, Interrogating the Spatial and Functional Relevance of Microbes in Pancreatic Cancer and Metastasis, FP00017880_Res1/ GRANT14022169, NIH/NCI, 7/1/2024-6/30/2029, \$3,253,966 (\$386,153/year)

Other

N/A

Completed

Principal Investigator-MDACC, 1%, Start-up funds, MDACC, 9/1/2014-8/31/2022, \$750,000

Principal Investigator, 10%, Development of Pancreatic Cancer High Risk Clinic, MD Anderson Cancer Center- Pancreatic Moon Shot project, 9/1/2015-8/31/2019, \$600,000

Co-Investigator, Immunotherapy for Pancreatic Cancer, Multiple Disciplinary Research Project, PI - Cassian Yee, 9/2016-present (\$30,000/year)

Principal Investigator, 5%, Preclinical PREVENT Cancer Program: Cancer Prevention by Alpha-Enolase Vaccination, N01CN-2015-000018 / HHSN26100003, NIH/NCI, 9/15/2016-2/14/2019 (\$556,210/year)

Co-Principal Investigator, 5%, Use of Hyperpolarization to detect Pancreatic Intraepithelial Neoplasias, American Association for Cancer Research (AACR), PI - Bhattacharya, 12/1/2016-11/30/2019, \$300,000

Principal Investigator, 15%, Influence of the gut microbiome on pancreatic cancer through modulation of the immune system, AGA-Bernard Lee Schwartz Research Scholar Award, 7/1/2017-6/30/2020, \$270,000

Principal Investigator, SUC2 - Intercepting Pancreatic Cancer in High Risk Cohorts, SUC2-AACR-DT25-17, American Association for Cancer Research (AACR), 2/1/2018-1/31/2022, \$171,304

Co-Investigator, 5%, SUC2-Intercepting Pancreatic Cancer in High Risk Cohorts, SUC2-AACR-DT25-17, SU2C, PI - Maitra / Lippman, 2/1/2018-7/31/2022, \$7,000,000

Co-Investigator, Pancreatic Moonshot Flagship Award, MD Anderson Cancer Center, 9/1/2018-8/30/2019

Principal Investigator, 1%, Manipulating the gut and tumor microbiome to improve pancreatic cancer outcomes, Fund 121454, Emerson Collective Award, 9/1/2018-7/1/2021, \$200,000

Principal Investigator, 5%, Manipulating the gut and tumor microbiome to induce anti-tumoral immune responses against pancreatic cancer., Emerson Collective Award, 11/1/2018-7/1/2021, \$200,000

Principal Investigator, 0.3 months, Modulating the Gut Microbiome for Prevention of Pancreatic Adenocarcinoma, 2019-00057035, Duncan Family Institute (DFI), 5/1/2019-4/30/2021, \$100,000

Principal Investigator, 3%, Modulating the Gut Microbiome for Prevention of Pancreatic Adenocarcinoma, Duncan Family Institute, 5/1/2019-5/30/2021, \$100,000

Principal Investigator, 5%, Modulating tumor immune responses by bacteria present in pancreatic cancer long-term survivors, Andrew Sabin Family Fellowship, 5/1/2019-7/30/2021, \$100,000

Co-Investigator, 1%, Pancreatic Moon Shot Philanthropic Funds, (Flagship 3), Development of Pancreatic Cancer High Risk Clinic, The University of Texas MD Anderson Cancer Center, 9/2019-8/31/2021, \$200,000 (\$200,000/year)

Principal Investigator, Usage of Fecal Microbiota Transplantation (FMT) for Immunomodulation in Cancer, CFS 710499-80-122165-21, M.D. Anderson Cancer Center/Moon Shot Fast Impact & Translation (FIT), 9/1/2019-8/31/2022, \$600,000

Principal Investigator, 10%, Usage of Fecal Microbiota Transplantation for Immunomodulation in Cancer, MD Anderson Moon Shot Fast Impact and Translation (FIT), 9/1/2019-8/31/2022, \$600,000

Principal Investigator, 10%, Modulating pancreatic cancer immunosuppression by fecal microbial transplants, V Foundation Translational Award, 11/1/2019-10/31/2023, \$600,000

Principal Investigator, 5%, Assessing the role of bacterial products in modulating cancer immune responses, Brown Foundation, 1/2020-1/2021, \$100,000

Co-Principal Investigator, 1%, Single-cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from in Situ to Invasive Breast Cancer, RP200120, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Piwnicka-Worms, 3/1/2020-2/28/2023, \$900,000

Principal Investigator, 5%, Genomic and therapeutic implications of selective bacterial and fungal colonization of gastrointestinal malignancies, Sharp Innovation Award (SU2C-AACR), 7/1/2020-6/30/2022, \$113,176

Principal Investigator, Human-to-mice fecal microbial transplants in pancreatic and colorectal cancer to sensitize tumors to immunotherapy, MD Anderson Cancer Center SPORE in Gastrointestinal Cancer - DRP Award, 1/1/2021-11/30/2021, \$100,000

Principal Investigator, 1%, Assessing spatial configuration and function of bacteria in pancreatic cancer and metastasis, Robert L. Fine Cancer Research Foundation, 1/1/2021-12/31/2023, \$250,000

Principal Investigator, 1%, PRIME-TR, MDACC/ Moon Shots, 9/1/2021-8/31/2023, \$2,551

Not Funded

N/A

Protocols

Funded

Principal Investigator, Repository of Blood, Urine, Cystic Fluid and Tissue from Patients at Risk for Pancreatic Cancer, PA16-0314, 2016

Principal Investigator, Analysis of the Microbiome in Patients with Gastrointestinal Cancer, at High Risk for Gastrointestinal Cancer, and Controls, PA16-0911, 2017

Principal Investigator, Prospective Genetic Registry for Individuals with Pancreatic Cancer active date, PA19-0178, 2019

Principal Investigator, Analysis of outcomes and predictive factors in pancreatic cancer surveillance program, PA19-0681, 2020-present

Principal Investigator, Pilot Study Using Fecal Microbial Transplants in Patients With Pancreatic Cancer, NCT04975217, 2021-present

Principal Investigator, Pilot Study Using Hyperpolarized ¹³C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection, NCT05873699, 2023-present

Unfunded

N/A

Patents and Technology Licenses

Patents

Wyeth LLC, University of Pittsburgh of the Commonwealth System of Higher Education, Jay K. Kolls, **Florencia Marine McAllister**, Beatriz M. Carreno, Samuel J. Goldman.

Characterization of IL-17F and IL-17R Interactions, United States, 7704503, 4/27/2010, Issued

MD Anderson Cancer Center, **McAllister F**, Erick Riquelme, Yu Zhang. Compositions and Methods for Treating Cancer Using 1L-17 Signaling Inhibitors and Immune Checkpoint Inhibitors., United States, 62/792,198, Filed

MD Anderson Cancer Center, **McAllister F**, Erick Riquelme, Yu Zhang. Tumor microbiome signature and therapeutic use of fecal microbiota transplantation on pancreatic cancer patients., United States, UTSC.P1401US.P1, Filed

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

CONICET/Agencia, Argentina Research Council, Reviewer, 2016-2017

NCI/PREVENT, NIH, Member, 2017-2019

PanCAN, AACR, Member, 2017-present

V Foundation, V Foundation Grants, Member, 2018-present

INSERM, NIH, Grant Reviewer, 2020-present

IRG, MDACC, Member, 2021-present

Academia Sinica, Taiwan, Member, 2022

PanCAN Career Development Award Scientific Review Committee, PanCAN, Member, 2023-present

The Israel Science Foundation, Research Grants, Israel, Member, 2023-present

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. **McAllister F**, Steele C, Zheng M, Young E, Shellito JE, Marrero L, Kolls JK. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol 172(2):1132-8, 1/2004. PMID: 14707088.

2. **McAllister F**, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, Pirhonen J, Kolls JK. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene- α and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. *J Immunol* 175(1):404-12, 7/2005. PMCID: PMC2849297.
3. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, **McAllister F**, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. *J Immunol* 175(9):6177-89, 11/2005. PMID: 16237115.
4. **McAllister F**, Steele C, Zheng M, Shellito JE, Kolls JK. In vitro effector activity of *Pneumocystis murina*-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. *Infect Immun* 73(11):7450-7, 11/2005. PMCID: PMC1273863.
5. Zheng M, Ramsay AJ, Robichaux MB, Kliment C, Crowe C, Rapaka RR, Steele C, **McAllister F**, Shellito JE, Marrero L, Schwarzenberger P, Zhong Q, Kolls JK. CD4+ T cell-independent DNA vaccination against opportunistic infections. *J Clin Invest* 115(12):3536-3544, 12/2005. e-Pub 11/2005. PMCID: PMCPMC1288835.
6. **McAllister F**, Ruan S, Steele C, Zheng M, McKinley L, Ulrich L, Marrero L, Shellito JE, Kolls JK. CXCR3 and IFN protein-10 in *Pneumocystis pneumonia*. *J Immunol* 177(3):1846-54, 8/2006. PMCID: PMC3912555.
7. McKinley L, Logar AJ, **McAllister F**, Zheng M, Steele C, Kolls JK. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. *J Immunol* 177(9):6215-26, 11/2006. PMCID: PMC3912571.
8. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, **McAllister F**, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. *Nat Med* 14(3):275-81, 3/2008. e-Pub 2/2008. PMCID: PMC2901867.
9. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, **McAllister F**, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat Med* 15(9):1016-22, 9/2009. e-Pub 8/2009. PMCID: PMC3034219.
10. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, **McAllister F**, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. *Cell* 148(1-2):349-61, 1/2012. PMCID: PMC3266542.
11. Laheru D, Shah P, Rajeshkumar NV, **McAllister F**, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. *Invest New Drugs* 30(6):2391-9, 12/2012. e-Pub 5/2012. PMCID: PMC3557459.
12. Bailey JM, Alsina J, Rasheed ZA, **McAllister FM**, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. *Gastroenterology* 146(1):245-56, 1/2014. e-Pub 10/2013. PMCID: PMC3910427.
13. **McAllister F**, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. *Cancer Cell* 25(5):621-37, 5/2014. PMCID: PMC4072043.
14. **McAllister F**, Pineda DM, Jimbo M, Lal S, Burkhardt RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. *Cancer Biol Ther* 15(6):688-98, 6/2014. e-Pub 3/2014. PMCID: PMC4049785.
15. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, Peterson SN, Snedrud EC, Borisy GG, Lazarev M, Stein E, Vadivelu J, Roslani AC, Malik AA, Wanyiri JW, Goh KL, Thevambiga I, Fu K, Wan F, Llosa N, Housseau F, Romans K, Wu X,

- McAllister FM**, Wu S, Vogelstein B, Kinzler KW, Pardoll DM, Sears CL. Microbiota organization is a distinct feature of proximal colorectal cancers. *Proc Natl Acad Sci U S A* 111(51):18321-6, 12/2014. e-Pub 12/2014. PMCID: PMC4280621.
16. Wang YJ, **McAllister F**, Bailey JM, Scott SG, Hendley AM, Leach SD, Ghosh B. Dicer is required for maintenance of adult pancreatic acinar cell identity and plays a role in Kras-driven pancreatic neoplasia. *PLoS One* 9(11):e113127, 2014. e-Pub 11/2014. PMCID: PMC4236134.
17. Borrás E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, **McAllister F**, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. *Cancer Prev Res (Phila)* 9(6):417-27, 6/2016. e-Pub 5/2016. PMCID: PMC4941624.
18. Bailey JM, Hendley AM, Lafaro KJ, Pruski MA, Jones NC, Alsina J, Younes M, Maitra A, **McAllister F**, Iacobuzio-Donahue CA, Leach SD. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. *Oncogene* 35(32):4282-8, 8/2016. e-Pub 11/2015. PMID: 26592447.
19. Bengsch F, Knoblock DM, Liu A, **McAllister F**, Beatty GL. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. *Cancer Immunol Immunother* 66(12):1609-1617, 12/2017. e-Pub 8/2017. PMCID: PMC5677559.
20. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, **McAllister F**, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 359(6371):97-103, 1/2018. e-Pub 11/2017. PMCID: PMC5827966.
21. Chung L, Orberg ET, Geis AL, Chan JL, Fu K, DeStefano Shields CE, Dejea CM, Fathi P, Chen J, Finard BB, Tam AJ, **McAllister F**, Fan H, Wu X, Ganguly S, Lebid A, Metz P, Van Meerbeke SW, Huso DL, Wick EC, Pardoll DM, Wan F, Wu S, Sears CL, Housseau F. *Bacteroides fragilis* Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. *Cell Host Microbe* 23(3):421, 3/2018. PMCID: PMC6469393.
22. Unver N, **McAllister F**. IL-6 Family Cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. *Cytokine Growth Factor Rev* 41:10-17, 6/2018. e-Pub 4/2018. PMCID: PMC6085880.
23. Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Vilar E, Wang TC, Bailey JM, **McAllister F**. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. *Gastroenterology* 155(1):210-223.e3, 7/2018. e-Pub 3/2018. PMCID: PMC6035075.
24. Chang K, Taggart MW, Reyes-Urbe L, Borrás E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, **McAllister F**, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. *JAMA Oncol* 4(8):1085-1092, 8/2018. PMCID: PMC6087485.
25. Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borrás E, Hasanov M, Varadhachary GR, Maitra A, Katz MH, Feng L, Futreal A, Fogelman DR, Vilar E, **McAllister F**. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. *Cancer Prev Res (Phila)* 11(11):679-686, 11/2018. e-Pub 10/2018. PMCID: PMC6343472.
26. Sahin I, Zhang Y, **McAllister F**. Tumor Spheres Quantification with Smoothed Euclidean Distance Transform. *J Mol Imaging Dyn* 8(1), 2018. e-Pub 7/2018. PMCID: PMC6179360.

27. Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaiparettu BA, **McAllister F**, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya PK. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. *Cells* 8(4), 4/2019. e-Pub 4/2019. PMCID: PMC6343472.
28. Mork M, Quesada PR, Bannon S, Montiel MF, Fleming JB, Lynch PM, Bhutani MS, Lee JH, **McAllister F**. Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome. *Pancreas* 48(4):e29-e30, 4/2019. PMCID: PMC6461374.
29. Vreeland TJ, **McAllister F**, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. *Pancreas* 48(6):837-843, 7/2019. PMID: 31210666.
30. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, **McAllister F**. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. *Cell* 178(4):795-806.e12, 8/2019. PMID: 31398337.
31. Singh K, Pruski MA, Polireddy K, Jones NC, Chen Q, Yao J, Dar WA, **McAllister F**, Ju C, Eltzschig HK, Younes M, Moran C, Karmouty-Quintana H, Ying H, Bailey JM. Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. *Oncogene* 39(5):1152-1164, 1/2020. e-Pub 9/2019. PMID: 31570790.
32. Cazacu IM, Luzuriaga Chavez AA, Mendoza TR, Qiao W, Singh BS, Bokhari RH, Saftoiu A, Lee JH, Weston B, Stroehlein JR, Kim MP, G Katz MH, Maitra A, **McAllister F**, Bhutani MS. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. *Endosc Ultrasound* 9(1):53-58, Jan-Feb, 1/2020. e-Pub 9/2019. PMCID: PMC7038729.
33. De Jesus-Acosta A, Sugar EA, O'Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, Zheng L, Begum A, Anders R, Maitra A, **McAllister F**, Rajeshkumar NV, Yabuuchi S, de Wilde RF, Batukbhai B, Sahin I, Laheru DA. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. *Br J Cancer* 122(4):498-505, 2/2020. e-Pub 12/2019. PMCID: PMC7029016.
34. Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, **McAllister F**, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients. *Clin Cancer Res* 26(6):1385-1394, 3/2020. e-Pub 12/2019. PMID: 31871297.
35. Dutta P, Pando SC, Mascaro M, Riquelme E, Zoltan M, Zacharias NM, Gammon ST, Piwnicka-Worms D, Pagel MD, Sen S, Maitra A, Shams S, **McAllister F**, Bhattacharya PK. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized ¹³C Metabolic Magnetic Resonance Spectroscopy. *Int J Mol Sci* 21(10), 5/2020. e-Pub 5/2020. PMCID: PMC7279395.
36. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, **McAllister F**, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med* 217(6), 6/2020. PMCID: PMC7161085.
37. Mendez R, Kesh K, Arora N, Di Martino L, **McAllister F**, Merchant N, Banerjee S, Banerjee S. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. *Carcinogenesis* 41(5):561-570, 7/2020. e-Pub 8/2019. PMCID: PMC7350554.
38. Wasylishen AR, Sun C, Moyer SM, Qi Y, Chau GP, Aryal NK, **McAllister F**, Kim MP, Barton MC, Estrella JS, Su X, Lozano G. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. *Sci Adv* 6(32):eaba8415, 8/2020. e-Pub 8/2020. PMCID: PMC7406367.

39. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, **McAllister F**. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. *Cancer Med* 9(15):5406-5415, 8/2020. e-Pub 6/2020. PMCID: PMC7402810.
40. Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, Zoltan M, Arora N, Baydogan S, Horne W, Burks J, Xu H, Hussain P, Wang H, Gupta S, Maitra A, Bailey JM, Moghaddam SJ, Banerjee S, Sahin I, Bhattacharya P, **McAllister F**. Interleukin-17 induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. *J Exp Med* 217(12), 12/2020. PMCID: PMC7953739.
41. Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, **McAllister F**, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. *Am J Respir Crit Care Med* 203(1):90-101, 1/2021. e-Pub 7/2020. PMCID: PMC7781147.
42. Singh K, Pruski M, Bland R, Younes M, Guha S, Thosani N, Maitra A, Cash BD, **McAllister F**, Logsdon CD, Chang JT, Bailey-Lundberg JM. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. *Lab Invest* 101(2):177-192, 2/2021. e-Pub 10/2020. PMCID: PMC8172380.
43. Enriquez JS, Chu Y, Pudukalakatti S, Hsieh KL, Salmon D, Dutta P, Millward NZ, Lurie E, Millward S, **McAllister F**, Maitra A, Sen S, Killary A, Zhang J, Jiang X, Bhattacharya PK, Shams S. Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer. *JMIR Med Inform* 9(6):e26601, 6/2021. e-Pub 6/2021. PMCID: PMC8277399.
44. Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, **McAllister F**, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylshen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. *Cancer Discov* 11(8):2094-2111, 8/2021. e-Pub 4/2021. PMCID: PMC8338884.
45. Sinha VC, Rinkenbaugh AL, Xu M, Zhou X, Zhang X, Jeter-Jones S, Shao J, Qi Y, Zebala JA, Maeda DY, **McAllister F**, Piwnicka-Worms H. Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. *Nat Commun* 12(1):5024, 8/2021. e-Pub 8/2021. PMCID: PMC8373912.
46. Riquelme E, **McAllister F**. Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer. *Cancer Cell* 39(9):1173-1175, 9/2021. e-Pub 9/2021. PMID: 34478640.
47. Brandi G, Turrone S, **McAllister F**, Frega G. The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? *Int J Mol Sci* 22(18), 9/2021. e-Pub 9/2021. PMCID: PMC8471697.
48. Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, **McAllister F**, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. *Cancer Prev Res (Phila)* 14(11):1021-1032, 11/2021. e-Pub 10/2021. PMCID: PMC8563400.
49. Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, Miller G, Pareek S, Rajaei H, Mohindroo C, Baydogan S, Ngo-Huang A, Parker N, Katz MHG, Petzel M, Vucic E, **McAllister F**, Schadler K, Winograd R, Bar-Sagi D. Exercise-induced engagement of the IL-15/IL-15R α axis promotes anti-tumor immunity in pancreatic cancer. *Cancer Cell* 40(7):720-737.e5, 7/2022. e-Pub 6/2022. PMCID: PMC9280705.
50. Kasliwal S, Baydogan S, Harrison D, Mork M, Maitra A, **McAllister F**. Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. *Gastroenterology* 163(1):316-318.e1, 7/2022. e-Pub 3/2022. PMCID: PMC9245458.

51. Mohindroo C, De Jesus-Acosta A, Yurgelun MB, Maitra A, Mork M, **McAllister F**. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. *Surg Pathol Clin* 15(3):491-502, 9/2022. e-Pub 8/2022. PMID: 36049831.
52. Kang Y, Deng J, Ling J, Li X, Chiang YJ, Koay EJ, Wang H, Burks JK, Chiao PJ, Hurd MW, Bhutani MS, Lee JH, Weston BR, Maitra A, Ikoma N, Tzeng CD, Lee JE, DePinho RA, Wolff RA, Pant S, **McAllister F**, Katz MH, Fleming JB, Kim MP. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. *J Clin Invest* 132(24):e151604. e-Pub 10/2022. PMCID: PMC9753992.
53. Mohindroo C, **McAllister F**, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. *Hematol Oncol Clin North Am* 36(5):1033-1051, 10/2022. e-Pub 9/2022. PMID: 36154786.
54. Quesada PR, Riquelme E, Burks J, Rakoski A, Sahin I, **McAllister F**. Assessment of the Murine Tumor Microenvironment by Multiplex Immunofluorescence. *Methods Mol Biol* 2435:107-127, 2022. PMID: 34993942.
55. Chandra V, **McAllister F**, Burks JK. Cytometry of Mass for Murine Immunoprofiling. *Methods Mol Biol* 2435:129-137, 2022. PMID: 34993943.
56. Pudakalakatti S, Raj P, Salzillo TC, Enriquez JS, Bourgeois D, Dutta P, Titus M, Shams S, Bhosale P, Kim M, **McAllister F**, Bhattacharya PK. Metabolic Imaging Using Hyperpolarization for Assessment of Premalignancy. *Methods Mol Biol* 2435:169-180, 2022. PMCID: PMC9352438.
57. Li L, Chandra V, **McAllister F**, Zhang Y. Mouse Models to Study Secondary Cancer Prevention. *Methods Mol Biol* 2435:215-223, 2022. PMID: 34993950.
58. Chang K, **McAllister F**, Vilar E. Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy. *Methods Mol Biol* 2435:95-105, 2022. PMID: 34993941.
59. Rupani DN, Thege FI, Chandra V, Rajaei H, Cowan RW, Wörmann SM, Le Roux O, Malaney P, Manning SL, Hashem J, Bailey-Lundberg J, Rhim AD, **McAllister F**. Adar1 deletion causes degeneration of the exocrine pancreas via Mavs-dependent interferon signaling. *Development* 150(2):dev201097, 1/2023. e-Pub 1/2023. PMCID: PMC10110501.
60. Díaz-Couselo FA, Flagel S, Nicolini C, Halac S, Manzano N, Aguirre M, Rébora J, Valle S, Noro L, Mohindroo C, **McAllister F**, Zylberman M. Impact of high neutrophil-to-lymphocyte ratio on survival in hospitalized cancer patients with COVID-19. *Cancer Med* 12(6):7164-7169, 3/2023. e-Pub 11/2022. PMCID: PMC9877941.
61. Faraoni EY, Singh K, Chandra V, Le Roux O, Dai Y, Sahin I, O'Brien BJ, Strickland LN, Li L, Vucic E, Warner AN, Pruski M, Clark T, Van Buren G, Thosani NC, Bynon JS, Wray CJ, Barsagi D, Poulsen KL, Vornik LA, Savage MI, Sei S, Mohammed A, Zhao Z, Brown PH, Mills T, Eltzschig HK, **McAllister F**, Bailey-Lundberg JM. CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer. *Cancer Res* 83(7):1111-1127, 4/2023. PMCID: PMC10071819.
62. Li G, Liu L, Lu T, Sui Y, Zhang C, Wang Y, Zhang T, Xie Y, Xiao P, Zhao Z, Cheng C, Hu J, Chen H, Xue D, Chen H, Wang G, Kong R, Tan H, Bai X, Li Z, **McAllister F**, Li L, Sun B. Gut microbiota aggravates neutrophil extracellular traps-induced pancreatic injury in hypertriglyceridemic pancreatitis. *Nat Commun* 14(1):6179, 10/2023. e-Pub 10/2023. PMCID: PMC10550972.
63. Deng N, Reyes-Urbe L, Fahrman JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, **McAllister F**, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-associated Immunity in Lynch Syndrome. *Clin Cancer Res* 29(21):4361-4372, 11/2023. e-Pub 9/2023. PMCID: PMC10618653.
64. Poplaski V, Bomidi C, Kambal A, Nguyen-Phuc H, Di Rienzi SC, Danhof HA, Zeng XL, Feagins LA, Deng N, Vilar E, **McAllister F**, Coarfa C, Min S, Kim HJ, Shukla R, Britton R, Estes MK, Blutt SE. Human intestinal organoids from Cronkhite-Canada syndrome patients reveal link between serotonin and proliferation. *J Clin Invest* 133(21), 11/2023. e-Pub 11/2023. PMCID: PMC10617781.

65. Riquelme E, Howell RM, **McAllister F**. Microbial Regulation of Vitamin D Linked to Colorectal Cancer: A Sex Bias. *Cancer Res* 83(22):3670-3672, 11/2023. PMID: 37964614.
66. Wright RD, Bartelli TF, Baydogan S, White JR, Kim MP, Bhutani MS, **McAllister F**. Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. *Front Immunol* 14:1268376, 2023. e-Pub 10/2023. PMCID: PMC10611524.
67. Baydogan S, Wright R, Kottoor RT, Kim M, Bhutani MS, **McAllister F**. Transient CA19-9 Elevation Post-Covid-19 Vaccine and Infection: A Case Series. *Gastro Hep Advances*, <https://doi.org/10.1016/j.gastha.2023.06.008>, 2023.
68. Chandra V, Li L, Le Roux O, Zhang Y, Howell RM, Rupani DN, Baydogan S, Miller HD, Riquelme E, Petrosino J, Kim MP, Bhat KPL, White JR, Kolls JK, Pylayeva-Gupta Y, **McAllister F**. Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. *Cancer Cell* 42(1):85-100.e6, 1/2024. e-Pub 12/2023. PMID: 38157865.
69. Castro Pando S, Li L, Mascaro M, Morgan R, Le Roux O, Faraoni EY, Romanin D, Riquelme E, Zhang Y, Kolls J, Allison J, Moghaddam S, **McAllister F**. Pancreatic epithelial IL-17/IL-17RA signaling drives B7-H4 to promote tumorigenesis. *Cancer Immunology Res*. In Press.

Invited Articles

1. Dubin PJ, **McAllister F**, Kolls JK. Is cystic fibrosis a TH17 disease? *Inflamm Res* 56(6):221-7, 6/2007. PMID: 17607545.
2. Zhong W, Kolls JK, Chen H, **McAllister F**, Oliver PD, Zhang Z. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. *Front Biosci* 13:1654-64, 2008. e-Pub 1/2008. PMID: 17981657.
3. **McAllister F**, Housseau F, Sears CL. Microbiota and immune responses in colon cancer: more to learn. *Cancer J* 20(3):232-6, 5/2014. PMID: 24855013.
4. **McAllister F**, Leach SD. Targeting IL-17 for pancreatic cancer prevention. *Oncotarget* 5(20):9530-1, 10/2014. PMCID: PMC4259416.
5. Zhang Y, **McAllister F**, Pasca di Magliano M. Immune cells in pancreatic cancer: Joining the dark side. *Oncoimmunology* 3:e29125, 2014. e-Pub 6/2014. PMCID: PMC4108467.
6. **McAllister F**, Kolls JK. Th17 cytokines in non-melanoma skin cancer. *Eur J Immunol* 45(3):692-4, 3/2015. PMCID: PMC4461870.
7. Roeser JC, Leach SD, **McAllister F**. Emerging strategies for cancer immunoprevention. *Oncogene* 34(50):6029-39, 12/2015. e-Pub 9/2015. PMID: 26364615.
8. **McAllister F**, Montiel MF, Uberoi GS, Uberoi AS, Maitra A, Bhutani MS. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. *Gastroenterol Hepatol (N Y)* 13(5):268-275, 5/2017. PMCID: PMC5479340.
9. Riquelme E, Maitra A, **McAllister F**. Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. *Cancer Discov* 8(4):386-388, 4/2018. PMID: 29610286.
10. **McAllister F** Khan MAW, Helmink B, Wargo JA. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. *Cancer Cell* 36(6):577-579, 12/2019. PMID: 31951558.
11. Chandra V, **McAllister F**. Therapeutic potential of microbial modulation in pancreatic cancer. *Gut* 70(8):1419-25. e-Pub 4/2021. PMCID: PMC8292583.
12. Li L, **McAllister F**. Too much water drowned the miller: Akkermansia determines immunotherapy responses. *Cell Rep Med* 3(5):100642, 5/2022. PMCID: PMC9133437.
13. Davidson NE, Gilbertson RJ, Letai A, Levine RL, **McAllister F**, Siu LL. Challenges and opportunities for physician-scientists in advancing cancer research. *Trends Cancer* 8(8):615-619, 8/2022. e-Pub 6/2022. PMID: 35717535.
14. Li L, **McAllister F**. A gut reaction can tune tumour fate during chemotherapy 615(7950):36-37, 2023. PMID: 36814015.
15. **McAllister F**. The Microbes in Tumors. *ViewPoint*, 2023.

Editorials

1. **McAllister F**, Mantegazza A, Garzón F, Rotbaum V, Remondino G, Vazquez Larsson M, Geffner J, Rabinovich GA, Bover L. [Use of convalescent plasma for COVID-19 treatment. History and evidence]. *Medicina (B Aires)* 80 Suppl 3:82-86, 2020. PMID: 32658853.

Other Articles

1. Vonderheide RH. Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. *Cancer Cell* 25(5):553-4, 5/2014. PMID: PMC4077610.
2. Cully M. Cancer: Targeting IL-17 in pancreatic cancer. *Nat Rev Drug Discov* 13(7):493, 7/2014. PMID: 24981357.
3. Stower H. Predicting pancreatic cancer survival via the tumor microbiome. *Nat Med* 25(9):1330, 9/2019. PMID: 31501604.
4. Bradley CA. Tumour microbiome defines outcomes. *Nat Rev Gastroenterol Hepatol*. e-Pub 9/2019. PMID: 31477872.

Abstracts

1. Zhang Y, Riquelme E, Zoltan M, **McAllister F**. IL 17 signaling modulates tumor microenvironment in pancreatic cancer. *Proceedings of the American Association for Cancer Research (AACR)*, 4/2019.
2. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jeng R, Wargo J, **McAllister F**. Pancreatic tumor microbiome and associated immune responses determine clinical outcomes. *Proceedings of the American Association for Cancer Research*, 4/2019.
3. Mohindroo C, Rogers JE, Hasanov M, Mizrahi J, Overman MO, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, **McAllister F**. A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer. *J Clin Oncol* (#e15781), 2019.
4. Montiel MF, Quesada PR, Dunseith M, Cazacu I, Luzuriaga A, Dong W, Mork, M, Feng L, You N, Vilar E, Arun, Brown P, Kim MP, Katz MHG, Maitra A, Bhutani MS, **McAllister F**. New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. *Clinical Oncology* (#e1512), 2019.
5. Hasanov M, Fogelman DR, Pant S, Katz MHG, Kim MP, Tzeng CWD, **McAllister F**. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. *J Clin Oncol* 37 (#e15773), 2019.

Book Chapters

1. Hasanov M, Montiel MF, Bhutani MS, **McAllister F**. Mechanisms and Evidence on Pancreatic Cancer Prevention. In: *Pancreatic Cancer: A Multidisciplinary Approach*. Springer, https://doi.org/10.1007/978-3-031-05724-3_25, e-Book 2022.

Books (edited and written)

1. **McAllister F**. Cancer Immunoprevention: Methods and Protocols. In: *Methods in Molecular Biology*, First Edition. Humana, 2022.

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

1. Screening for High Risk Population - Development of Algorithm, 2017, <https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/screening/screening-pancreatic-web-algorithm.pdf>.

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Scientific Editor, *Cancer Discovery*, American Association for Cancer Research, 2023-2026

Member of Editorial Review Board

N/A

Journal Reviewer

AdHoc Reviewer, *Clinical Cancer Prevention*, 2015-present

AdHoc Reviewer, Clinical Cancer Research, 2015-present

AdHoc Reviewer, Gastroenterology, 2015-present

AdHoc Reviewer, Gut, 2015-present

AdHoc Reviewer, Nature Biotechnology, 2015-present

AdHoc Reviewer, Science/ Science Advances, 2019-present

AdHoc Reviewer, Cell, 2020-present

Other Editorial and Review Activities

Research Proposal, The Israel Science Foundation, The Israel Science Foundation, 2023

TEACHING

Teaching Within Current Institution - GSBS

Formal Teaching

Courses Taught

Instructor, Advanced Immunology, GSBS
6/2017-present

Instructor, Basic Immunology, GSBS
6/2017-present

Course Co-Director, Biology of Cancer Metastasis, GSBS
6/2019-present

Course Director, Core Immunology Course, GSBS
2022-present

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

Member, GSBS, Ruoji Zhou, 6/2015-3/2016

Member, GSBS, Joseph Weygrand, 9/2015-6/2017

Member, GSBS, Paul Kurywachak, 9/2015-1/2018

Member, GSBS, Rosa Carrero, 9/2016-9/2022

Member, GSBS, Krishnan Mahadevan, 11/2016-present

Member, Michael Curren, 6/2017-9/2022

Member, GSBS, Paulina Horton, 6/2017-9/2022

Member, GSBS, Arthur Liu, 6/2017-present

Committee Chair, GSBS, Susana Castro-Pando, 9/2017-12/2017

Member, GSBS, Priyank Raj, 9/2017-12/2018

Committee Chair, GSBS, Dhvani Rupani, 9/2017

Committee Chair, GSBS, Vidhi Chandra, 1/2018-3/2018

Member, GSBS, Deborah Silverman, 6/2018-6/2022

Member, GSBS, Parin Shah, 6/2018-6/2022

Member, GSBS, Rhiannon Morrissey, 6/2018-present

Member, GSBS, GSBS, Xiaojie Yang, 9/2018-present

Member, Xiaoyin Liu, TRIUMPH Postdoctoral Fellow, 12/2018-present

Committee Chair, GSBS, Rian Morgan, 1/2019-3/2019

Member, GSBS, Paiawan Seyed, 7/2019-9/2022

Member, Yuejiang Liu, PhD candidate, 9/2022-present

Supervisory Committees

N/A

Examining Committees

Committee Chair, GSBS, Dhvani Rupani, PhD Candidacy, 2019

Research Mentor, GSBS, Paiawan Seyed, Masters Degree Candidacy, 2019

Research Mentor, GSBS, Paul Kurywchak, PhD Candidacy, 2019

Research Mentor, GSBS, Rhiannon Morrissey, PhD Candidacy, 2019

Member, GSBS, Anna Schucheng Miao, PhD, 9/2023-present

Direct Supervision

Undergraduate and Allied Health Students

Michelle Zoltan, 5/2015-8/2016

Taylor Ann Yurchyk, 2/2017-5/2017

Amanda I. Rakoski, 6/2018-7/2018

Sini Koivu, 7/2021-8/2021

Andrew Nkrumah, 6/2023-8/2023

Banoo Khani, 6/2023-8/2023

Medical Students

Ekrem Turk, 7/2015-9/2015

Pompeyo Quesada, 8/2017-4/2018

Graduate Students

Rosa Maria Santana Carrero, 9/2015-12/2015

Chao-Hsien Chen, 1/2016-3/2016

Anchit Bhagat, 3/2017-5/2017

Olujimi Olowokere, 8/2017-12/2017

Lourdes Susana Castro Pando, 9/2017-9/2022

Akash Ramniklal Boda, 1/2018-3/2018

Vidhi Chandra, 1/2018-5/2023

Benjamin Thomas Whitfield, 5/2018-8/2018

Michael Joseph Clowers, 1/2019-3/2019

Rian Howell, 6/2019-present

Committee Chair, Dhvani Rupani, 1/2021-6/2023

Committee Chair, Haoyue Liu, 6/2022-present

Maria Grimaldo, 10/2022-present

Committee Chair, Hajar Rajaei, 1/2023-present

Postdoctoral Research Fellows

Yu Zhang, MD, PhD, 2/2015-12/2018

Marilina Mascaro, PhD, 4/2016-5/2017

Erick Riquelme, PhD, 3/2017-2019
Le Li, MD, PhD, 12/2019-present
Qianfei Zheng, PhD, 9/2020-10/2021
Jeong-Hoon Jang, PhD, 9/2020-1/2023
Vidhi Chandra, 5/2023-present
Amirhossein Mohseni, 7/2023-present
Amirsaman Ashtari, 7/2023-present
Sedigheh Taghinezhadsaroukalaei, 7/2023-present

Clinical Residents and Fellows

Merve Hasanov, MD, Melanoma Fellow, 6/2018-present
Robert Hester, MD, Heme-Onc Fellow, 1/2020-present
Victoria Serpa, MD, Heme-Onc Fellow, 6/2020-present

Other Supervisory Teaching

Zhou Yu, Visiting Scholar, 8/2015-1/2016
Harikumar Kuzhuvelil Bhaskaran Nair, Visiting Scholar, 10/2015
Maria Fernanda Montiel, MD, Research Investigator, 1/2016-2020
Erick Riquelme, PhD, Research Investigator, 4/2016-2020
Anchit Bathwa, Rotating Graduate Students, 3/2017-5/2017
Susana Castro-Pando, Rotating Graduate Students, 9/2017-12/2017
Akash Badi, Rotating Graduate Students, 1/2018-3/2018
Vidhi Chandra, Rotating Graduate Students, 1/2018-3/2018
Alexei Quesada Nides, Research Intern, 1/2018-7/2018
Rian Morgan, Rotating Graduate Students, 1/2019-3/2019
Chirayu Mohindroo, Visiting Student, 1/2019-6/2020
Payten Ten-Hagen, APRN, 12/2019
Yu Zhang, Short term research collaborator, 12/2019
Alex Cooper, APRN, 1/2020
Chasity Yajima, APRN, 1/2020
Pompeyo Rafael Quesada, Observer, 1/2020-2/2020
Jessica Thomas, APRN, 3/2020

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Instructor, Descriptive Anatomy Course, National University of Rosario, Medical School
Pre-Admission Preparatory Course, Rosario, Santa Fe, Argentina
8/1997-3/1998

Instructor, General Pharmacology Course, National University of Rosario, Medical School
3/2000-6/2002

Cold Springs Harbor Course, Virtual
6/2020

Training Programs

N/A

Other Formal Teaching

N/A

**Supervisory Teaching
Committees**

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

PhD advisory, UTH, Llaran Turner, 10/2022-present

Medical Students

N/A

Graduate Students

UTHSC, Olujimi Babajide Olowokere, 7/2016-7/2018

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

High School, Michael Onipede, High School student, 7/2017-8/2017

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Symposia on Cancer Research 2020, MD Anderson Cancer Center, Houston, TX, Co-chair,
Organizing Committee, 2020

University of California Pancreatic Cancer Consortium, Keynote Speaker, 2023

Global Cancer Consortium Pancreatic Cancer Mini-Symposium, Keynote Speaker, 2/2023

Presentations at National or International Conferences

Invited

III National Convention of Teaching Assistants in Pharmacology, National University of the
Northeast, Corrientes, Argentina, 11/1999

McAllister F, Galmarini D. Comparative Study of Dosing Regimens in the United States and
Argentina: Antiarrhythmic, Anticonvulsive and Antihypertensive Drugs, Research Day at
National University of Rosario, Santa Fe, Argentina, 12/1999

Pediatric Pulmonary Research Conference, University of Pittsburgh, Pittsburgh, PA, 12/2003

T Cells and Pathogens Symposium - Experimental Biology, American Association of
Immunologists Meeting, Washington, DC, 4/2004

Wilkinsburg Meeting, Wilkinsburg, PA, Wilkinsburg, PA, 6/2004

Cystic Fibrosis Retreat, Children's Hospital of Pittsburgh, Pittsburgh, PA, 8/2004

Pediatric Pulmonary Research Seminar, Children's Hospital of Pittsburgh, Pittsburgh, PA,
9/2004

Cystic Fibrosis, XVIII Annual North American Cystic Fibrosis Conference, St. Louis, MO,
10/2004

Allergy/Immunology Conference, University of Pittsburgh, Pittsburgh, PA, 11/2004

Cytokine Therapeutics, Keystone Immunology Meeting, Santa Fe, NM, 2/2005

Cystic Fibrosis, XIX Annual North American Cystic Fibrosis Conference, Baltimore, MD, 10/2005

Medicine Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3/2007

Clinical Pharmacology Seminar, Johns Hopkins University, Baltimore, MD, 10/2011

Microenvironment Symposium, AACR Annual Meeting, Chicago, IL, 4/2012

Cancers of the Pancreas and Small Bowel, GI ASCO Meeting, San Francisco, CA, 1/2013

Koc University School of Medicine, Research Seminar, Turkey, 2/2013

Research Seminar, Koc University School of Medicine, Turkey, 2/2013

Pancreatic cancer symposium, AACR, Washington, DC, 4/2013

Pancreatic Cancer, Pancreatic Cancer Action Network, CA, 10/2013

Amgen Guest Speaker, Immunology Seminar, AMGEN, Los Angeles, CA, 3/2015

Early detection of pancreatic cancer and chemoprevention, Digestive Disease Week, Washington, DC, 5/2015

Metabolomics Symposium, MD Anderson Cancer Center, Houston, TX, 10/2015

School of Exact and Natural Sciences, University of Buenos Aires, 12/2015

Special guest speaker, Hospital Posadas, Buenos Aires, Argentina, 12/2015

Updates in Pancreatic Cancer Research, PanCAN Speaker for Community Education, Houston, TX, 2/2016

Keynote Speaker, Pancreatic Cancer Research Group/ ASCO, Chicago, IL, 5/2016

Pancreatic Disease, Gigi Shaw Arledge Conference, Columbia University, New York, NY, 10/2017

Special Guest Speaker, British Hospital, Buenos Aires, Argentina, 10/2017

Presentation, American Pancreatic Association, San Diego, CA, 11/2017

Presentation, SU2C, Los Angeles, CA, 2/2018

Immunology Seminar, AMGEN, Los Angeles, CA, 3/2018

Presenter, V Foundation Summit, Fairfax, VA, 4/2018

Poster Presentation: Pancreatic cancer immunoprevention: Novel strategies, AACR Annual Meeting, Chicago, IL, 4/14/2018

Digestive Disease Week, Symposia Speaker, Washington, DC, 6/2018

Immune Systems and Treatment Responses, Digestive Disease Week, Washington, DC, 6/2018

Poster Presentation: High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer., ASCO, Chicago, IL, 6/2018

Digestive Disease Week, San Diego, CA, 6/2019

The pancreatic tumor microenvironment and the influence of the gut-tumor bacterial axis, Spanish National Cancer Research (CNIO), Madrid, Spain, 7/26/2019

Targeting Th17 Cells for the Prevention of Pancreatic Cancer, International Cancer Prevention Society (ICAPS), London, United Kingdom, 9/10/2019

Genomic and therapeutic implications of selective bacterial and fungal colonization of gastrointestinal malignancies., SU2C, Santa Monica, CA, 1/2020

SLAGO, Society of Latin-American GI-Oncologists, SLAGO, Society of Latin-American GI-Oncologists, Virtual Conference, 4/2021

Tumor Microbiome in Pancreatic Cancer, AACR Annual Meeting, Virtual Conference, 4/2021

NETosis in Pancreatic Cancer and COVID-19 AACR Annual Meeting, AACR Annual Meeting, Virtual Conference, 5/2021

Pancreatic Cancer: Microbes and their Induced Traps, Westlake University, Virtual Conference, 8/10/2021

Hereditary pancreatic cancer. Concepts and recommendations, Virtual Conference, Argentina, 9/29/2021

The Role of Microbes and their Induced NETs in Pancreatic Cancer, NYU Langone Health, Perlmutter Cancer Center Special Research Seminar Series, New York, NY, 3/22/2022

Metabolism and Microbiome, AACR Pancreatic Cancer Conference, Boston, MA, 9/16/2022

Microbiome within Pancreatic Tumors and Impact on Immune Microenvironment, Society for Immunotherapy of Cancer, Boston, MA, 11/10/2022

Targeting the Tumor Microenvironment to Overcome Immune Resistance: Strategies and Future Directions session, ASCO GI Cancers Symposium, San Francisco, CA, 1/20/2023

Plenary Session: The Phillip A. Sharp Innovation In Collaboration Awards, SU2C Scientific Summit, Coronado, CA, 1/31/2023

Mechanisms employed by the gut and tumor microbiome to mediate responses to immunotherapy, AACR Annual Meeting, Orlando, FL, 4/18/2023

Role of Microbes in Initiation of Progression and Response to Treatment of Pancreatic Cancer, 2023 Seminars of the Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Santa Fe, Argentina, 4/25/2023

Understanding the role of the microbiome in cancer formation, progression and treatment, Cell Press, Virtual, 6/28/2023

Plenary Session 8: Therapeutic Opportunities in Tumor Stromal and Immune Microenvironments, AACR Special Conference: Pancreatic Cancer, Boston, MA, 9/2023

Microbiome and Tumor Immunology, CRO-Aviano, Inaugural MD Anderson Cancer Center and CRO-Aviano Symposium, Aviano, Italy, 9/20/2023

Tumor resident microbes influencing immune responses., International Cancer Immunotherapy Conference CICON23, Milan, Italy, 9/23/2023

Microbial Matters in Cancer, Thursday Seminar Series, Salk Institute for Biological Studies, La Jolla, CA, 11/2/2023

Microbial Matters in Cancer, TAMEST, UTHSA Mays Cancer Center (MCC) Grand Rounds, San Antonio, TX, 11/16/2023

Mechanisms employed by the tumor microbiome to mediate responses to immunotherapy, ESMO Immuno-Oncology Congress 2023., Geneva, Switzerland, 12/6/2023

Other, Including Scientific Exhibitions

Zhang Z, Song K, **McAllister F**, Zhang P, Zhong Q, Kolls JK. Generation of M3-FLAG Fusion Protein as A Broad-Spectrum Chemokine Antagonist for Various Disease Models, New Orleans, LA, 1/2003

T Cells and Pathogens Symposium, American Association of Immunologists International Meeting, Washington, DC, 4/2004

Lymphocytes as Effector and Regulatory Cells in TB and Pulmonary Infections Symposium, American Thoracic Society International Conference, Orlando, FL, 5/2004

Role of IL-17 and IL-23 in Cystic Fibrosis, Keystone Immunology Meeting, Cytokine Therapeutics, Santa Fe, NM, 2/2005

McAllister F, Kraemer K. A Healthy Woman with Acute Dyspnea and Chest Pain: The Importance of family history., Society of General Internal Medicine, Toronto, Canada, 4/2007

Bailey JM, Alsina J, Rasheed Z, Fu YY, **McAllister F**, Zhang H, Pasricha P, Matsui W, Maitra A, Leach SD. Pancreatic cancer tumor initiating cells are marked by the presence of cell surface acetylated alpha tubulin, Pancreatic Cancer AACR Meeting, Lake Tahoe, NV, 6/2012

McAllister F, Bailey JM, Roeser JC, Wick E, Sears C, Kolls JK, Drake C, Pardoll DM, Leach SD. Th17 cells in early pancreatic tumorigenesis, AACR Pancreatic Cancer 2012, Lake Tahoe, NV, 6/2012

McAllister F and Leach SD. Role of IL-17 pathway in pancreatic cancer initiation, AACR International Meeting, San Diego, CA, 4/2013

Current Topics in Genetics, University of Texas Graduate School, TX, 9/2014

Targeting TH17 cells in pancreatic ductal adenocarcinoma, PanCAN Retreat, Los Angeles, CA, 10/2014

Zhang Y, Sahin I, Gupta S, Maitra A, Leach S., Bailey J and **McAllister F**. IL-17 induces pancreatic cancer stemness, AACR Special Meeting on Pancreatic Cancer, Orlando, TX, 5/2016

IAP/LAPSG Join Meeting, UCA, Buenos Aires, Argentina, 10/2017

Workshop speaker, Pancreatic Cancer Tumor Microenvironment, AACR Annual Meeting, Atlanta, GA, 3/2019

Oral Discussant: New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program, ASCO, Chicago, IL, 6/2019

Role of Intra-Tumoral Microbes in Pancreatic Cancer and Interaction with Gut Microbes, Society for Immunotherapy of Cancer (SITC), Orlando, FL, 2/2020

Role of the Microbiome, AACR, Orlando, FL, 2/2020

The Microbiome as a Regulator of the Immune Tumor Microenvironment - Implications of finding bacteria in pancreatic tumors, AACR, Virtual Conference, 6/2020

Role of the gut-tumor microbial axis in pancreatic ductal adenocarcinoma (PDAC), AACR, Virtual Conference, 9/29/2020

APA Virtual Meeting, APA, Virtual Conference, 11/2020

Immunology Meeting, Immunology, Chile, 11/2020

Microbiome in pancreatic cancer" and "Risk groups and strategies for early detection, IATTGI, S. Oncologia Del Hospital Udaondo, 9/1/2021

Presentation in Argentina, Virtual Talk, Argentina, 9/8/2021

Advances in hereditary pancreatic cancer. Genes involved and their impact on prognosis, treatment and prevention, La Academia de Ciencias Medicas de Cordoba, Virtual Conference, Argentina, 9/23/2021

Keynote for NCCC Scientific Retreat, Dartmouth Geisel School of Medicine, Virtual Conference, 11/8/2021

FIT TEAM: FMT, Moon Shots Scientific Seminar, Virtual Seminar, 2/23/2022

Microbes in pancreatic cancer, from function to early detection, PRIME-TR, 3rd Annual Virtual PRIME-TR Retreat, Virtual Conference, 2/24/2022

Premalignant lesions: diagnosis, treatment and surveillance, Latin American Symposium of Oncological Gastroenterology, SLAGO, Viña del Mar, Chile, 4/20/2023

Seminar Invitations from Other Institutions

Adult Pulmonary Research Seminar, Louisiana State University, New Orleans, LA, 3/2003
Cystic Fibrosis Retreat, Children's Hospital of Pittsburgh, Pittsburgh, 8/2004
Pediatric Pulmonary Research Seminar, Children's Hospital of Pittsburgh, Pittsburgh, PA, 9/2004
Clinical Pharmacology Seminar, Johns Hopkins University, Baltimore, MD, 11/2011
The role of the microbial gut-tumor axis in pancreatic tumorigenesis, UNC Seminar, Virtual Conference, 11/2020
The Yin & Yang of Immunity in Cancer, Annual UNC Lineberger Scientific Symposium, Virtual Seminar, 4/2021
Role of Microbes in Shaping Immune Responses in Cancer and Beyond, Yale Pancreatic Cancer Collaborative Seminar Series, Yale University, Virtual Seminar, 5/20/2021
The Emergent Role of Microbes in Shaping Cancer Initiation and Therapy Responses, A.C. Camargo Cancer Center, Virtual Conference, 6/25/2021
Microbial Matters in Pancreatic Cancer – From Inception to Progression, University of North Carolina, UNC Lineberger Seminar Series, Chapel Hill, NC, 9/2022
Microbial matters in Pancreatic Cancer, Massachusetts General Hospital / Harvard, MGH GI Grand Rounds, Virtual, 10/11/2022
Chemical biology and synthetic biology methods, Baylor College of Medicine, BCM Pharmacology & Chemical Biology department, Virtual Seminar, 11/8/2022
Microbial Matters in Pancreatic Cancer, Dartmouth College of Medicine, Microbiology and Immunology Seminar, Hanover, NH, 12/15/2022
Texas Symposium on Critical Topics in Immunology, Texas A&M University, College Station, TX, 2/18/2023
Microbial matters in pancreatic cancer, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 4/3/2023

Lectureships and Visiting Professorships

Distinguished Lecturer Seminar IBT, Texas A & M Health & Science Center, Houston, TX, 6/27/2016
Mary Beth Maddox Award Lecture, Excellence in Immunology Lecture Series, UT Southwestern, Dallas, TX, 5/22/2024

Other Presentations at State and Local Conferences

Current Topics in Genetics, University of Texas Graduate school, TX, 9/2014
Immune Cells Inducing Cancer Stemness, Advances in Oncology Ground Rounds, MD Anderson Cancer Center, Houston, TX, 10/2015
Metabolomics Symposium, MD Anderson Cancer Center, Houston, TX, 10/2015
Hereditary Pancreatic Cancer, Advances in Oncology Ground Rounds, MD Anderson Cancer Center, Houston, TX, 12/2015
Development of Pancreatic Cancer High Risk clinic, CCSG Retreat, Houston, TX, 11/2016
Hereditary Pancreatic Cancer, Medicine Ground Rounds, MD Anderson Cancer Center, Houston, TX, 11/2016
Technological advanced in Science, Town Hall Virtual Meeting, MD Anderson Cancer Center, HOUSTON, TX, 12/2020
CP Member Science, 2022 CCSG RDO/CP Programmatic and DCPPS Faculty Retreat, DCPPS, MD Anderson Cancer Center, Virtual, 4/29/2022

Immune-Microbiome Biomarker Discovery, 2022 Leading Edge of Cancer Research Symposium, MD Anderson Cancer Center, Houston, TX, 11/18/2022

Modulating the Gut and Tumor Microbiome in Pancreatic Cancer, Shelby-Lavine Pancreatic Cancer Research Symposium, Virtual, 5/9/2023

Real-time metabolic imaging for early detection of pancreatic cancer, Monthly Abdominal Imaging Research Lecture Series (MARS), MD Anderson Cancer Center, Virtual, 8/24/2023

Mary Beth Maddox Award, Blaffer Lecture Series, MD Anderson Cancer Center, Genetics, Houston, TX, 9/12/2023

Microbial matters in pancreatic cancer, Division of Cancer Medicine Grand Rounds, MD Anderson Cancer Center, Houston, TX, 10/10/2023

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American College of Physicians
Member, 2009-2013

American Society of Clinical Pharmacology and Therapeutics
Member, 2/2009-2013

American Association of Cancer Research
Member, 1/2010-present

American Society of Clinical Oncology
Member, 1/2010-present

Digestive Diseases Center, Houston, TX
Member, 3/2016-present

American Gastroenterological Association
Member, 5/2016-present

American Association for Cancer Research (AACR)
Member, Tumor Microenvironment Section of the Tumor Biology (TB) Subcommittee, 2022

American Association of Cancer Research (AACR)
Member, Cancer Molecular Imaging and Theranostics (CMIT) Task Force, 2023-present

American Association of Cancer Research (AACR)
Chair, Tumor Microenvironment Section of the Tumor Biology Subcommittee, 2023-2024

Local/State

GSBS Tumor Immunology Steering Committee
Member, 1/2019-present

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

1/25/2024